MedEsthetics magazines offers business education and in-depth coverage of the latest noninvasive cosmetic procedures for physicians and practice managers working in the medical aesthetics industry.
Issue link: https://medesthetics.epubxp.com/i/468544
78 MARCH 2015 | Med Esthetics REVANCE BEGINS INJECTABLE BTXA TRIAL Biopharmaceutical company Revance Therapeutics has announced the initia- tion of the Phase 2 BELMONT trial—a randomized, double-blind, dose ranging, active and placebo controlled, multicenter study to evaluate the safety, effi cacy and duration of effect of RT002, a botulinum toxin type A injectable. Intended to treat glabellar lines, RT002 is an investigational product designed to offer more targeted delivery of botulinum toxin to treatment sites. Combining a proprietary, pure 150kD botulinum toxin type A molecule—without any acces- sory proteins or animal-derived compo- nents—with TransMTS peptide delivery technology, the company notes that RT002 also has the potential to address additional therapeutic indications where more targeted delivery is required or lon- ger duration is desired, e.g., in movement disorders, urology or ophthalmology. Approximately 250 subjects are expected to enroll at up to 10 sites in Canada. Primary endpoints include investigators' assessment of glabellar line severity at maximum frown at week 24, and median duration of effect from the date of treatment back to baseline severity. Participants will be random- ized one-to-one across fi ve study arms receiving one of three doses of RT002, the labeled dose of BOTOX Cosmetic or placebo. "The opportunity for a longer-lasting, more targeted neurotoxin is tremendous as it offers the potential for improved patient satisfaction and safety with longer- lasting results," said Dan Browne, co- founder, president and CEO of Revance Therapeutics. "Based on the current progress of our program, we expect to report top-line data from this Phase 2 study in late 2015." ALPHAEON ACQUIRES CLARION ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings, has completed its acquisition of Clarion Medical Technologies for $55 million in a combination of cash and equity plus performance-based earnouts. Clarion, based in Canada, has more than 100 employees, 36 sales representatives and over 40 product licenses. "We are excited to have Clarion join ALPHAEON," said Robert E. Grant, CEO of ALPHAEON. "We view Clarion as a leading provider of lifestyle healthcare products in Canada and are thrilled to combine their products and experience with our platform." MODERNIZING MEDICINE ACQUIRES AESYNTIX Electronic health record developer Modernizing Medicine has completed its purchase of Aesyntix Health, a California- based fi rm that provides billing and inven- tory services to healthcare professionals. In addition to the cloud-based Electronic Medical Assistant (EMA), Modernizing Medicine is now able to offer customers revenue cycle management, inventory management and a medical group pur- chasing organization. "We are excited to join forces with Modernizing Medicine; it is a win all around," said Clark Avery, CEO of Aesyntix. "Not only will the employees be part of a rapidly growing and leading healthcare technology company with a clear mission of modernizing medicine through specialty solutions, but also our customers can benefi t from the stronger combined offerings." GARY D. MONHEIT, MD, AWARDED TOP ASDS HONOR Gary D. Monheit, MD, of Total Skin & Beauty Dermatology Center in Birming- ham, Alabama, received the American Society for Dermatologic Surgery (ASDS) Samuel J. Stegman, MD, Award for Dis- tinguished Service—the Society's highest honor. The tribute recognizes members who have made a substantial contribution to advance ASDS goals in the areas of edu- cation, organized service and/or research. A long-standing member and past president of the ASDS, Dr. Monheit received the very fi rst ASDS Resident Scholarship and is a fi rst-generation Mohs surgeon, having personally trained with Frederic E. Mohs, MD. In his early career, he also trained with some of the fi rst ASDS members, including Dr. Stegman. Dr. Monheit has been a fi xture on the ASDS Annual Meeting faculty, participated in and chaired work groups, trained two generations of fellows, helped conduct studies for the U.S. Food and Drug Ad- ministration, and is a traveling mentor and legislative liaison. "Dr. Monheit is renowned for his enthusiastic support of dermatologic surgery through his commitment to ASDS as well as to teaching, patient care and academic advancement of the fi eld," said Roy G. Geronemus, MD, the 2013 Stegman Award winner. "He is a sought-after teacher and mentor. He has trained multiple fellows for the ACGME-approved fellowship and he is among the leading dermatologic surgeons in the world." IBM COLLABORATING ON DERMATOLOGIC COGNITIVE COMPUTER IMAGING IBM is teaming up with Memorial Sloan Kettering to develop cognitive visual computing that can analyze dermatologi- cal images of skin lesions. The technolo- gy "learns" by identifying specifi c patterns in medical images. Their goal is to help physicians identify cancerous lesions earlier in treatment. In preliminary experiments—using a controlled research dataset of specialized NEWS & EVENTS Gary D. Monheit, MD, (left) receives the Stegman award from ASDS President George J. Hruza, MD, MBA.